Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim R Kalden

Showing results (1-10 of 87) with videos related to

Pageof 9
Sort By:
The Journal of Rheumatology. Supplement|November 19, 2002
Expanding role of biologic agents in rheumatoid arthritisJoachim R Kalden
Rheumatology and Therapy|October 18, 2016
Emerging Therapies for Rheumatoid ArthritisJoachim R Kalden
Arthritis Research|July 12, 2002
Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesJoachim R Kalden
Annals of the New York Academy of Sciences|August 30, 2005
Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?Reinhard E Voll, Joachim R Kalden
Arthritis Research|July 12, 2002
Perspectives for TNF-alpha-targeting therapiesHanns-Martin Lorenz, Joachim R Kalden
Arthritis Research & Therapy|June 1, 2011
Advances in rheumatology: new targeted therapeuticsPaul P Tak, Joachim R Kalden
Nature Reviews. Rheumatology|November 22, 2017
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatmentJoachim R Kalden, Hendrik Schulze-Koops
Arthritis Research & Therapy|July 14, 2009
Stress of different types increases the proinflammatory load in rheumatoid arthritisRainer H Straub, Joachim R Kalden
Biochemical Pharmacology|October 14, 2003
The putative role of apoptosis-modified histones for the induction of autoimmunity in Systemic Lupus ErythematosusChristoph Gabler, Joachim R Kalden, Hanns-Martin Lorenz
Autoimmunity Reviews|May 16, 2006
Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-StudyKarin Manger, Ludwig Wildt, Joachim R Kalden, et al.
Pageof 9

Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
The Journal of Rheumatology. Supplement|November 19, 2002
Expanding role of biologic agents in rheumatoid arthritisJoachim R Kalden
Rheumatology and Therapy|October 18, 2016
Emerging Therapies for Rheumatoid ArthritisJoachim R Kalden
Arthritis Research|July 12, 2002
Emerging role of anti-tumor necrosis factor therapy in rheumatic diseasesJoachim R Kalden
Annals of the New York Academy of Sciences|August 30, 2005
Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?Reinhard E Voll, Joachim R Kalden
Arthritis Research|July 12, 2002
Perspectives for TNF-alpha-targeting therapiesHanns-Martin Lorenz, Joachim R Kalden
Arthritis Research & Therapy|June 1, 2011
Advances in rheumatology: new targeted therapeuticsPaul P Tak, Joachim R Kalden
Nature Reviews. Rheumatology|November 22, 2017
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatmentJoachim R Kalden, Hendrik Schulze-Koops
Arthritis Research & Therapy|July 14, 2009
Stress of different types increases the proinflammatory load in rheumatoid arthritisRainer H Straub, Joachim R Kalden
Biochemical Pharmacology|October 14, 2003
The putative role of apoptosis-modified histones for the induction of autoimmunity in Systemic Lupus ErythematosusChristoph Gabler, Joachim R Kalden, Hanns-Martin Lorenz
Autoimmunity Reviews|May 16, 2006
Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-StudyKarin Manger, Ludwig Wildt, Joachim R Kalden, et al.
Pageof 9